Translational Research in Breast Cancer (SPORE)

乳腺癌转化研究 (SPORE)

• 批准号: 9127157
• 负责人: C KENT OSBORNE
• 金额: $ 216.2万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-19 至 2019-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9127157
• 关键词: Adverse effects; Affect; Antigen Targeting; Apoptosis; Biometry; Breast; Breast Cancer Patient; Breast Cancer Prevention; Cellular biology; Chemoprevention; Clinical; Clinical Sciences; Clinical Trials; Combined Modality Therapy; Development; ERBB2 gene; Endocrine; Environment; Growth; Immunosuppressive Agents; Immunotherapy; Laboratory Finding; Lesion; Malignant Neoplasms; Mammary Gland Parenchyma; Molecular Biology; Mus; Neoplasm Metastasis; Oncogene Activation; Outcome; Pathology; Pathway interactions; Patients; Phosphotransferases; Pre-Clinical Model; Premalignant; Prevention; Quality of life; Research; Research Personnel; Resistance; Resources; Safety; Science; Specificity; Steroid Receptors; T-Lymphocyte; Technology; Translational Research; Translations; Treatment Failure; Tumor Antigens; Tumor Bank; anticancer research; bisphosphonate; breast lesion; career development; cellular engineering; chemotherapy; cytokine; cytotoxicity; efficacy testing; hormone therapy; improved; inhibitor/antagonist; malignant breast neoplasm; mevalonate; mouse model; neoplastic cell; overexpression; preclinical study; prevent; programs; public health relevance; receptor; tissue resource; tumor growth; upstream kinase

DESCRIPTION (provided by applicant): Translational research, adapting new laboratory findings quickly to improve prevention, quality of life, and survival for breast cancer patients, hs been the focus of the team now forming the Baylor Breast Center for over 30 years. In the early years of our previous SPORE, our tumor bank which made much of this rapid translation possible became a national resource, while basic cell and molecular biology research suggested new clinical implications for endocrine and chemotherapy resistance, breast cancer prevention, metastasis, and development of premalignant lesions. Developmental projects ranged even further in seeking new translational possibilities. In this new SPORE proposal, we build on our earlier results and on new findings and technologies, in four projects and several support components. (1) We have discovered that the mevalonate pathway is upregulated by anti-HER2 therapy and can serve as an escape pathway, leading to treatment failure. But several already approved agents (statins and bisphosphonates) can inhibit this pathway, and we will explore their mechanisms and their potential to overcome this treatment failure, both in preclinical studies and a clinical trial. (2)The steroid receptor coactivator SRC-3 is frequently overexpressed in breast cancer and promotes growth and endocrine resistance, especially when HER2 is also active. Finding that inhibiting upstream kinases PKC and PKD that support SRC-3 activity can suppress tumor growth and restore endocrine sensitivity, we propose to dissect the functions of these kinases on SRC-3 in defined preclinical models, and test the efficacy and safety of a PKC inhibitor added to endocrine therapy in a clinical trial. (3) Chemoprevention of breast cancer has had limited acceptance due to expense and concerns about side effects of long-term continuous treatment with existing agents. But we have now discovered that activated pSTAT5 blocks the apoptosis that is typically induced as a protective mechanism by activation of oncogenes, and that even short-term suppression of pSTAT5 with agents like ruxolitinib can cause regression of premalignant breast lesions and prevent progression to cancer in mice. In both mouse models and an early clinical trial, we will investigate this approach for effective intermittent chemoprevention. (4) Though immunotherapy promises exquisite specificity and safety, results have been disappointing as tumor cells alter targeted antigens and generate an immunosuppressive environment to escape. Here we propose to adoptively transfer T cells engineered to attack two tumor-associated antigens rather than one, and to express a chimeric receptor that causes the repressive cytokine 1L4 to promote T cell cytotoxicity instead. Our unique, widely used breast Tissue Resource/Pathology Core, along with Biostatistics and Administrative Cores give key support to this SPORE. Our highly successful Developmental Projects and Career Development programs will continue to encourage new ideas and new investigators in translational breast cancer research.

描述（由申请人提供）：转化研究，快速适应新的实验室发现，以提高预防，生活质量和乳腺癌患者的生存率，一直是团队的重点，现在形成贝勒乳腺中心超过30年。在我们之前的SPORE的早期，我们的肿瘤库使这种快速翻译成为可能，成为国家资源，而基础细胞和分子生物学研究表明，内分泌和化疗耐药性，乳腺癌预防，转移和癌前病变的发展具有新的临床意义。发展项目在寻求新的翻译可能性方面甚至走得更远。 在这个新的SPORE提案中，我们在四个项目和几个支持组件中建立了我们早期的结果和新的发现和技术。(1)我们已经发现，甲羟戊酸途径被抗HER 2治疗上调，并且可以作为逃逸途径，导致治疗失败。但是几种已经批准的药物（他汀类药物和双膦酸盐）可以抑制这一途径，我们将在临床前研究和临床试验中探索它们的机制和克服这种治疗失败的潜力。（2）类固醇受体辅激活因子SRC-3在乳腺癌中经常过表达，并促进生长和内分泌抵抗，特别是当HER 2也活跃时。发现抑制支持SRC-3活性的上游激酶PKC和PKD可以抑制肿瘤生长并恢复内分泌敏感性，我们建议在定义的临床前模型中剖析这些激酶对SRC-3的功能，并在临床试验中测试PKC抑制剂添加到内分泌治疗中的有效性和安全性。(3)乳腺癌的化学预防由于费用和对现有药物长期连续治疗副作用的担忧而受到限制。但我们现在发现，激活的pSTAT 5阻断了通常由癌基因激活作为保护机制诱导的细胞凋亡，并且即使用ruxolitinib等药物短期抑制pSTAT 5也可以导致癌前乳腺病变的消退并防止小鼠癌症的进展。在小鼠模型和早期临床试验中，我们将研究这种有效的间歇性化学预防方法。(4)尽管免疫疗法承诺了精确的特异性和安全性，但结果令人失望，因为肿瘤细胞改变了靶抗原并产生了免疫抑制环境来逃避。在这里，我们建议过继转移T细胞工程攻击两个肿瘤相关抗原，而不是一个，并表达嵌合受体，导致抑制性细胞因子1 L4，以促进T细胞的细胞毒性，而不是。我们独特的、广泛使用的乳腺组织资源/病理学核心，沿着生物统计学和管理核心，为该SPORE提供了关键支持。我们非常成功的发展项目和职业发展计划将继续鼓励转化乳腺癌研究中的新想法和新研究人员。